Showing results (281-290 of 319) with videos related to
Sort By:
Pageof 32
Gynecologic Oncology|January 27, 2023
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN studyDavid Cibula, Huseyin Akilli, Jiri Jarkovsky, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2024
Consensus on surgical technique for sentinel lymph node dissection in cervical cancerNicolò Bizzarri, Andreas Obermair, Heng-Cheng Hsu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2024
Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M Slomovitz, David Cibula, Weiguo Lv, et al.The New England Journal of Medicine|December 6, 2023
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerKathleen N Moore, Antoine Angelergues, Gottfried E Konecny, et al.The New England Journal of Medicine|July 3, 2024
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical CancerIgnace Vergote, Antonio González-Martín, Keiichi Fujiwara, et al.The Lancet. Oncology|April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trialToon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.The Lancet. Oncology|July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.Pageof 32